Trial Profile

Special Access Scheme(SAS) program for melanoma patients who have failed checkpoint inhibitor or targeted therapy

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tavokinogene telseplasmid (Primary)
Indications Malignant melanoma
Focus Therapeutic Use
Sponsors OncoSec Medical

Most Recent Events

03 Jun 2019 New trial record
29 May 2019 According to an OncoSec Medical Media release, the company has entered into an collaboration agreement with Emerge Health for commercializing its proprietary TAVO(enhanced IL-12 DNA-plasmid) and making it available under Australia's Special Access Scheme in 2019 for melanoma patients.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com